
Bis(maltolato)oxovanadium(IV)
CAS No. 38213-69-3
Bis(maltolato)oxovanadium(IV) ( BMOV | Bis(maltolato)oxovanadium (IV) )
产品货号. M27534 CAS No. 38213-69-3
BMOV 是一种有效、可逆、竞争性和口服活性的泛 PTP(蛋白酪氨酸磷酸酶)抑制剂,具有模拟胰岛素作用和抗糖尿病特性。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥316 | 有现货 |
![]() ![]() |
10MG | ¥478 | 有现货 |
![]() ![]() |
25MG | ¥988 | 有现货 |
![]() ![]() |
50MG | ¥1596 | 有现货 |
![]() ![]() |
100MG | ¥2535 | 有现货 |
![]() ![]() |
200MG | ¥3791 | 有现货 |
![]() ![]() |
500MG | ¥6099 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称Bis(maltolato)oxovanadium(IV)
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述BMOV 是一种有效、可逆、竞争性和口服活性的泛 PTP(蛋白酪氨酸磷酸酶)抑制剂,具有模拟胰岛素作用和抗糖尿病特性。
-
产品描述BMOV is a potent, reversible, competitive and orally active pan-PTP (protein tyrosine phosphatases)inhibitor with insulin-mimicking effects and anti-diabetic properties. BMOV is a potent insulin sensitize. BMOV is shown to improve cardiac dysfunctions in diabetic models. BMOV inhibits HCPTPA, PTP1B, HPTPβ and SHP2 with IC50s of 126 nM, 109 nM, 26 nM and 201 nM, respectivelyr.(In Vitro):BMOV treatment enhances the phosphorylation of the insulin receptor and of the insulin signalling key intermediate Akt. BMOV treatment also resultes in an increased glucose uptake in C2C12 cells.(In Vivo):BMOV (0.75-3.0 mmol; intraperitoneal injection; twice weekly; for 6 weeks; Male C57BL/6J mice) treatment ameliorates the metabolic phenotype, as evidenced by reduced body weight, improved insulin sensitivity and glucose tolerance.
-
体外实验Bis(maltolato)oxovanadium(IV) treatment enhances the phosphorylation of the insulin receptor and of the insulin signalling key intermediate Akt. Bis(maltolato)oxovanadium(IV) (BMOV; 50 μM) treatment also resultes in an increased glucose uptake in C2C12 cells.
-
体内实验Bis(maltolato)oxovanadium(IV) (BMOV; 0.75-3.0 mmol; intraperitoneal injection; twice weekly; for 6 weeks; C57BL/6J mice) treatment ameliorates the metabolic phenotype. Liver, skeletal muscle, and adipose tissue revealed a significantly reduced PTP activity in all analysed tissues compared to HFD mice. Animal Model:C57BL/6J mice (4-6 weeks) fed with high-fat diet (HFD) Dosage:0.75-3.0 mmol Administration:Intraperitoneal injection; twice weekly; for 6 weeks Result:Ameliorated the metabolic phenotype, as evidenced by reduced body weight, improved insulin sensitivity and glucose tolerance.
-
同义词BMOV | Bis(maltolato)oxovanadium (IV)
-
通路Metabolic Enzyme/Protease
-
靶点Phosphatase
-
受体Apoptosis
-
研究领域——
-
适应症——
化学信息
-
CAS Number38213-69-3
-
分子量317.15
-
分子式C12H10O7V
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : 25 mg/mL (78.83 mM)
-
SMILESCC(OC=C1)=C([O-]2)C1=O[V+2]23(O=C4C=COC(C)=C4[O-]3)=O
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Ha TJ, Kubo I. Lipoxygenase inhibitory activity of anacardic acids. J Agric Food Chem. 2005 Jun 1;53(11):4350-4.